Top

Published in:

01-05-2013 | Original Article

Comparison of inflammatory response after implantation of sirolimus- and paclitaxel-eluting stents in patients on hemodialysis

Authors: Hideki Yano, Shigeo Horinaka, Hiroshi Yagi, Toshihiko Ishimitsu

Published in: Heart and Vessels | Issue 3/2013

Abstract

Because systemic inflammation after coronary intervention places patients at increased risk of subsequent cardiac events, we aimed to compare clinical outcomes and chronic serum inflammation markers of paclitaxel-eluting stents (PES) and sirolimus-eluting stents (SES) in hemodialysis patients. Paclitaxel-eluting stents and SES were implanted in 36 patients with 46 lesions, and 32 patients with 40 lesions, respectively. In addition to 1-year major adverse cardiac event (MACE) rates, high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6), neopterin, intercellular adhesion molecule 1 (ICAM-1) and vascular cell adhesion molecule 1 (VCAM-1) were also compared before and 9 months after percutaneous coronary intervention (PCI). The incidence of MACE was significantly lower in the PES group than in the SES group (11.1 vs. 25.0 %, respectively, P = 0.042), mainly due to the reduction of target lesion revascularization in the PES group (6.5 vs. 17.5 %, P = 0.003). The logarithm of hs-CRP as well as IL-6 decreased significantly 9 months post-PCI compared with pre-PCI in the PES group (hs-CRP: 3.65 ± 0.35 vs. 2.91 ± 0.48, P = 0.007; IL-6: 6.73 ± 3.66 vs. 2.61 ± 2.29, P = 0.017) but not in the SES group (hs-CRP: 3.33 ± 0.29 vs. 3.42 ± 0.27, P not significant; IL-6: 6.08 ± 4.97 vs. 5.66 ± 4.29, P not significant). However, neopterin, ICAM-1, and VCAM-1 remained unchanged both pre-PCI and 9 months post-PCI in both groups. Moreover, MACE were less frequent in patients with decreased hs-CRP levels 9 months post-PCI compared with patients without decreased hs-CRP levels (P = 0.002) in all patients. Paclitaxel-eluting stents appear to be more effective than SES in reducing MACE rates, especially target lesion revascularization, and may be able to stabilize local inflammatory changes of target lesions specifically in patients on hemodialysis. Thus PES, which inhibit in-stent restenosis and cardiac events in hemodialysis patients, may play an important role in suppression of chronic inflammatory response in target lesions as compared with SES. Chronic continuous inflammation plays an important role after implantation of both types of stent with regard to in-stent restenosis in patients on hemodialysis.

Cheung AK, Sarnak MJ, Yan G, Berkoben M, Heyka R, Kaufman A, Lewis J, Rocco M, Toto R, Windus D, Ornt D, Levey AS, HEMO Study Group (2004) Cardiac diseases in maintenance hemodialysis patients: results of the HEMO Study. Kidney Int 65:2380–2389PubMedCrossRef

Herzog CA, Ma JZ, Collins AJ (2002) Comparative survival of dialysis patients in the United States after coronary angioplasty, coronary artery stenting, and coronary artery bypass surgery and impact of diabetes. Circulation 106:2207–2211PubMedCrossRef

Gruberg L, Dangas G, Mehran R, Mintz GS, Kent KM, Pichard AD, Satler LF, Lansky AJ, Stone GW, Leon MB (2002) Clinical outcome following percutaneous coronary interventions in patients with chronic renal failure. Catheter Cardiovasc Interv 55:66–72PubMedCrossRef

Das P, Moliterno DJ, Charnigo R, Mukherjee D, Steinhubl SR, Sneed JD, Booth DC, Ziada KM (2006) Impact of drug-eluting stents on outcomes of patients with end-stage renal disease undergoing percutaneous coronary revascularization. J Invasive Cardiol 18:405–408PubMed

Yachi S, Tanabe K, Tanimoto S, Aoki J, Nakazawa G, Yamamoto H, Otsuki S, Yagishita A, Kishi S, Nakano M, Taniwaki M, Sasaki S, Nakajima H, Mise N, Sugimoto T, Hara K (2009) Clinical and angiographic outcomes following percutaneous coronary intervention with sirolimus-eluting stents versus bare-metal stents in hemodialysis patients. Am J Kidney Dis 54:299–306PubMedCrossRef

Halkin A, Selzer F, Marroquin O, Laskey W, Detre K, Cohen H (2006) Clinical outcomes following percutaneous coronary intervention with drug-eluting vs bare-metal stents in dialysis patients. J Invasive Cardiol 18:577–583PubMed

Kim JY, Ko YG, Shim CY, Park S, Hwang KC, Choi D, Jang Y, Chung N, Shim WH, Cho SY (2005) Comparison of effects of drug-eluting stent versus bare metal stents on plasma C-reactive protein levels. Am J Cardiol 96:1384–1388PubMedCrossRef

Ozer N, Tangurek B, Firat F, Ozer S, Tartan Z, Ozturk R, Ozay B, Ciloglu F, Yilmaz H, Cam N (2008) Effects of drug-eluting stents on systemic inflammatory response in patients with unstable angina pectoris undergoing percutaneous coronary intervention. Heart Vessels 23:75–82PubMedCrossRef

Windecker S, Remondino A, Eberli FR, Jüni P, Räber L, Wenaweser P, Togni M, Billinger M, Tüller D, Seiler C, Roffi M, Corti R, Sütsch G, Maier W, Lüscher T, Hess OM, Egger M, Meier B (2005) Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N Engl J Med 353:653–662PubMedCrossRef

10.

Morice MC, Colombo A, Meier B, Serruys P, Tamburino C, Guagliumi G, Sousa E, Stoll HP, REALITY Trial Investigators (2006) Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial. JAMA 295:895–904PubMedCrossRef

11.

Pires NM, Eefting D, de Vries MR, Quax PH, Jukema JW (2007) Sirolimus and paclitaxel provoked different vascular pathological responses after local delivery in a murine model for restenosis on underlying atherosclerotic arteries. Heart 93:922–927PubMedCrossRef

12.

Kang WC, Ahn TH, Moon CI, Han SH, Shin EK, Kim JS, Ko YG, Choi D, Jang Y, Kim BK, Oh SJ, Jeon DW, Yang JY (2009) Comparison of inflammatory markers and angiographic outcomes after implantation of sirolimus and paclitaxel-eluting stents. Heart 95:970–975PubMedCrossRef

13.

Li JJ, Zhang YP, Wang C, Gao LJ, Qin XW, Xu B, Chen JL, Yang YJ, Gao RL (2009) Impact of direct sirolimus-eluting stent implantation on the early systemic inflammatory response compared with complementary stent implantation. Coron Artery Dis 20:65–70PubMedCrossRef

14.

Gaspardone A, Versaci F (2005) Coronary stenting and inflammation. Am J Cardiol 96:65L–70LPubMedCrossRef

15.

Versaci F, Gaspardone A (2004) Prevention of restenosis after stenting: the emerging role of inflammation. Coron Artery Dis 15:307–311PubMedCrossRef

16.

Cirillo P, Golino P, Calabrò P, Calì G, Ragni M, De Rosa S, Cimmino G, Pacileo M, De Palma R, Forte L, Gargiulo A, Corigliano FG, Angri V, Spagnuolo R, Nitsch L, Chiariello M (2005) C-reactive protein induces tissue factor expression and promotes smooth muscle and endothelial cell proliferation. Cardiovasc Res 68:47–55PubMedCrossRef

17.

Li JJ, Li J, Nan JL, Li Z, Zhen X, Mu CW, Dai J, Zhang CY (2007) Coronary restenotic reduction of drug-eluting stent may be due to its anti-inflammatory effects. Med Hypotheses 69:1004–1009PubMedCrossRef

18.

Yazdani S, Simon AD, Vidhun R, Gulotta C, Schwartz A, Rabbani LE (1998) Inflammatory profile in unstable angina versus stable angina in patients undergoing percutaneous interventions. Am Heart J 136:357–361PubMedCrossRef

19.

Ferrante G, Niccoli G, Biasucci LM, Liuzzo G, Burzotta F, Galiuto L, Trani C, Rebuzzi AG, Crea F (2008) Association between C-reactive protein and angiographic restenosis after bare metal stents: an updated and comprehensive meta-analysis of 2747 patients. Cardiovasc Revasc Med 9:156–165PubMedCrossRef

20.

Toutouzas K, Colombo A, Stefanadis C (2004) Inflammation and restenosis after percutaneous coronary interventions. Eur Heart J 25:1679–1687PubMedCrossRef

21.

Pasceri V, Willerson JT, Yeh ET (2000) Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 102:2165–2168PubMedCrossRef

22.

Niccoli G, Montone RA, Ferrante G, Crea F (2010) The evolving role of inflammatory biomarkers in risk assessment after stent implantation. J Am Coll Cardiol 56:1783–1793PubMedCrossRef

23.

Yano H, Horinaka S, Iemura T, Ishimura K, Yagi H, Yabe A, Ishimitsu T (2011) Comparison of the chronic anti-inflammation effects after implantation of drug eluting stent and bare metal stent. Shinzo 43:1319–1327 (in Japanese)

24.

Otsuka M, Toyofuku M, Watanabe N, Motoda C, Kawase T, Takeda R, Mito S, Tamekiyo H, Okimoto T, Hirao H, Muraoka Y, Ueda H, Masaoka Y, Hayashi Y (2011) Clinical usefulness of drug-eluting stents in the treatment of dialysis patients with coronary artery disease. EuroIntervention 6:754–759PubMedCrossRef

25.

Higashitani M, Mori F, Yamada N, Arashi H, Kojika A, Hoshi H, Minami Y, Yamaguchi J, Yamauchi T, Takagi A, Ogawa H, Hagiwara N (2011) Efficacy of paclitaxel-eluting stent implantation in hemodialysis patients. Heart Vessels 26:582–589PubMedCrossRef

26.

Raggi P, Boulay A, Chasan-Taber S, Amin N, Dillon M, Burke SK, Chertow GM (2002) Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol 39:695–701PubMedCrossRef

27.

Bocksch W, Fateh-Moghadam S, Mueller E, Huehns S, Waigand J, Dietz R (2005) Percutaneous coronary intervention in patients with end-stage renal disease. Kidney Blood Press Res 28:275–279PubMedCrossRef

28.

Fujii K, Mintz GS, Kobayashi Y, Carlier SG, Takebayashi H, Yasuda T, Moussa I, Dangas G, Mehran R, Lansky AJ, Reyes A, Kreps E, Collins M, Colombo A, Stone GW, Teirstein PS, Leon MB, Moses JW (2004) Contribution of stent underexpansion to recurrence after sirolimus-eluting stent implantation for in-stent restenosis. Circulation 109:1085–1088PubMedCrossRef

29.

Kuriyama N, Kobayashi Y, Nakayama T, Kuroda N, Komuro I (2006) Images in cardiovascular medicine. Damage to polymer of a sirolimus-eluting stent. Circulation 114:e586–e587PubMedCrossRef

30.

Tamekiyo H, Hayashi Y, Toyofuku M, Ueda H, Sakuma T, Okimoto T, Otsuka M, Imazu M, Kihara Y (2009) Clinical outcomes of sirolimus-eluting stenting after rotational atherectomy. Circ J 73:2042–2049PubMedCrossRef

31.

Aoyama T, Ishii H, Toriyama T, Takahashi H, Kasuga H, Murakami R, Amano T, Uetani T, Yasuda Y, Yuzawa Y, Maruyama S, Matsuo S, Matsubara T, Murohara T (2008) Sirolimus-eluting stents vs bare metal stents for coronary intervention in Japanese patients with renal failure on hemodialysis. Circ J 72:56–60PubMedCrossRef

32.

Moussa I, Ellis SG, Jones M, Kereiakes DJ, McMartin D, Rutherford B, Mehran R, Collins M, Leon MB, Popma JJ, Russell ME, Stone GW (2005) Impact of coronary culprit lesion calcium in patients undergoing paclitaxel-eluting stent implantation (a TAXUS-IV sub study). Am J Cardiol 96:1242–1247PubMedCrossRef

33.

London GM, Guérin AP, Marchais SJ, Métivier F, Pannier B, Adda H (2003) Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transpl 18:1731–1740CrossRef

34.

Levin AD, Vukmirovic N, Hwang CW, Edelman ER (2004) Specific binding to intracellular proteins determines arterial transport properties for rapamycin and paclitaxel. Proc Natl Acad Sci USA 101:9463–9467PubMedCrossRef

35.

Patterson C, Mapera S, Li HH, Madamanchi N, Hilliard E, Lineberger R, Herrmann R, Charles P (2006) Comparative effects of paclitaxel and rapamycin on smooth muscle migration and survival: role of AKT-dependent signaling. Arterioscler Thromb Vasc Biol 26:1473–1480PubMedCrossRef

36.

Luc G, Arveiler D, Evans A, Amouyel P, Ferrieres J, Bard JM, Elkhalil L, Fruchart JC, Ducimetiere P, PRIME Study Group (2003) Circulating soluble adhesion molecules ICAM-1 and VCAM-1 and incident coronary heart disease: the PRIME Study. Atherosclerosis 170:169–176PubMedCrossRef

37.

Adachi T, Naruko T, Itoh A, Komatsu R, Abe Y, Shirai N, Yamashita H, Ehara S, Nakagawa M, Kitabayashi C, Ikura Y, Ohsawa M, Yoshiyama M, Haze K, Ueda M (2007) Neopterin is associated with plaque inflammation and destabilisation in human coronary atherosclerotic lesions. Heart 93:1537–1541PubMedCrossRef

Title: Comparison of inflammatory response after implantation of sirolimus- and paclitaxel-eluting stents in patients on hemodialysis
Authors: Hideki Yano
Shigeo Horinaka
Hiroshi Yagi
Toshihiko Ishimitsu
Publication date: 01-05-2013
Publisher: Springer Japan
Published in: Heart and Vessels / Issue 3/2013
Print ISSN: 0910-8327
Electronic ISSN: 1615-2573
DOI: https://doi.org/10.1007/s00380-012-0250-9

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Comparison of inflammatory response after implantation of sirolimus- and paclitaxel-eluting stents in patients on hemodialysis

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2013

Adverse cardiovascular outcomes associated with concurrent use of clopidogrel or ticlopidine and proton-pump inhibitors in patients undergoing percutaneous coronary intervention

Effects of the left ventricular assist device on the compliance and distensibility of the carotid artery

Left ventricular aneurysm repair without ventriculotomy

Prediction of carotid plaques in hypertensive patients by risk factors, left ventricular hypertrophy, and epicardial adipose tissue thickness

Left atrial thickness under the catheter ablation lines in patients with paroxysmal atrial fibrillation: insights from 64-slice multidetector computed tomography

Are high-potency statins in low dose “strong statins”?

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page